Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent DTaP-IPV-Hep B-PRP-T Vaccine at Two, Four and Six Months of Age Compared With Licensed Vaccines in Latin America
The Pediatric Infectious Disease Journal, 07/31/2012
Macías M et al. – This new, fully liquid acellular pertussis hexavalent vaccine demonstrated less reactogenicity than the licensed comparator whole cell pertussis vaccine and was highly immunogenic for the new Hep B valence.



